Physician profile
Ronald J Renuart
NPI 1467420778
$879.94
in general payments reported to CMS, 2019-2025
15 companies · $176 in 2025
The $176 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.84 · 2022: $52.08 · 2023: $274 · 2024: $366 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $816.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $144.64 | 2023-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $139.64 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $126.08 | 2024 | Capvaxive |
| Glaxosmithkline, LLC. | $123.96 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Abiomed | $78.86 | 2025 | |
| Novartis Pharmaceuticals Corporation | $37.80 | 2022-2023 | |
| Sanofi Pasteur INC. | $36.92 | 2023-2024 | |
| Boston Scientific Corporation | $36.32 | 2025 | General - Pain Management |
| Novo Nordisk INC | $33.75 | 2019-2023 | |
| Lilly USA, LLC | $28.14 | 2022-2024 | Zepbound, Jardiance |
| Astellas Pharma US INC | $23.34 | 2023 | Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.22 | 2023 | |
| Idorsia Pharmaceuticals US INC | $18.39 | 2023 | Quviviq |
| Dexcom, INC. | $17.96 | 2023 | Dexcom G6 Transmitter |
| Abbott Laboratories | $13.92 | 2025 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Renuart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.